Rani Therapeutics Gets Ball Rolling On Oral Stelara Biosimilar

Three Phase I Biosimilar Trials Planned For 2023, Including Stelara And Humira Rivals

 
• By Dean Rudge

California-based Rani Therapeutics has provided several key pipeline updates and targets, ahead of plans to accelerate development of its proprietary RaniPill Go ‘robotic’ capsule technology in 2023.

Image of an IV drip, often used in chemotherapy
Rani is attempting to differentiate from typical infusion biologics • Source: Shutterstock

More from Biosimilars

More from Products